An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary) ; JNJ 64264681 (Primary) ; JNJ 70218902 (Primary) ; JNJ-74856665 (Primary) ; JNJ-75348780 (Primary) ; Onametostat (Primary) ; Safimaltib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 03 Feb 2025 New trial record